Interferon vs. adenine arabinoside 5'-monophosphate in patients with anti-HBe-positive chronic hepatitis

Journal of Medical Virology

Volumn 49, Issue 4, 1996, Pages 325-328

  Buti, Maria ^a   Jardi, Rosendo ^a   Rodriguez Frias, Francisco ^a   Allende, Helena ^a   Cotrina, Montserrat ^a   Esteban, Rafael ^a   Guardia, Jaime ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adenine arabinoside 5' monophosphate; Anti HBe; Interferon

Indexed keywords

ALPHAN1 INTERFERON; INTERFERON; VIDARABINE PHOSPHATE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEPATITIS VIRUS; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERONS; LIVER; MALE; MIDDLE AGED; VIDARABINE PHOSPHATE;

EID: 0029741297     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199608)49:4<325::AID-JMV11>3.0.CO;2-9     Document Type: Article

References (13)

1. Alberti A, Fattovich G, Farci P, et al. (1991): Favorable response to lymphoblastoid Interferon of anti-HBe and HBV-DNA positive chronic hepatitis. In Hollinger FB, Lemon SM, Margolis HS (eds): "Viral Hepatitis and Liver Disease." Baltimore: Williams and Wilkins, pp 645-647.
2. Bertoletti A, Sette A, Chisari FV, et al. (1994): Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407-410.
3. Bonino F, Brunetto MR (1993): Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. Journal of Hepatology 18:5-8.
4. Brunetto MR, Oliveri F, Rocca G, et al. (1989): Natural course and response to Interferon of chronic hepatitis B accompanied by antibody to hepatitis B antigen. Hepatology 10:198-202.
5. Brunetto M, Giarin M, Saracco G, et al. (1993): Hepatitis B virus unable to secrete e antigen and response to Interferon in chronic hepatitis B. Gastroenterology 205:845-850.
6. Carman WF, Jacyna MR, Hadziyannis S, et al. (1989): Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 2:588-591.
7. Carman W, Thomas H, Domingo E (1993): Viral genetic variation: Hepatitis B virus as a clinical example. Lancet 341:349-353.
8. Fattovich G, Farci P, Rugge M, et al. (1992): Randomized controlled trial of lymphoblastoid Interferon alfa in patients with chronic hepatitis lacking HBeAg. Hepatology 15:584-589.
9. Hadziyannis SL, Lieberman HB, Karvountzis GG, et al. (1983): Analysis of liver disease, nuclear HBcAg, viral replication and hepatitis B virus DNA in the liver and serum HBeAg vs antiHBe-positive carriers of hepatitis B virus. Hepatology 3:656-62.
10. Hadziyannis S, Bramou T, Makris A, et al. (1990): Interferon α-2 treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. Journal of Hepatology 11:s133-s136.
11. Marcellin P, Pouteau M, Loriot MA, et al. (1995): Adenine-arabinoside 5′-monophosphate in patients with chronic hepatitis B: Comparison of the efficacy in patients with high and low viral replication. Gut 36:422-426.
12. Pastore G, Santantonio T, Milella M, et al. (1992): Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. Journal of Hepatology 14:221-225.
13. Rodriguez-Frias F, Buti M, Arranz JA, et al. (1994): Detection of hepatitis B precore mutants by the fluorescent linear PCR sequencing method. Journal of Hepatology 21:934-939.